CBO421 / Cidara Therap - LARVOL DELTA

Cidara Therapeutics Restructures Workforce to Focus on Planned Clinical Development of CD388 (GlobeNewswire) - "Cidara Therapeutics...announced a reduction in its workforce to focus on the clinical development of CD388, the Company’s novel DFC candidate for influenza A and B. The planned reduction impacts approximately 30% of the Cidara workforce....These strategic initiatives are expected to substantially reduce capital needs and allow Cidara to focus on its planned Phase 2b and potential subsequent trials investigating CD388 as a single-dose, universal preventative for influenza A and B. The Company continues business development discussions for its oncology DFC programs, including CBO421, a CD73 inhibitor..."

Pipeline update • Infectious Disease • Influenza • Oncology • Solid Tumor

Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results (GlobeNewswire) - "IND Clearance for CBO421: Cidara received investigational new drug application (IND) clearance for CBO421 in July 2024."

IND • Solid Tumor

Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire) - "We have multiple key catalysts expected this year, including the filing of an Investigational New Drug Application (IND) in mid-2024 for CBO421, a potential best-in-class inhibitor of CD73."

IND • Oncology

CBO421: A novel drug Fc-conjugate to prevent tumor immune evasion via the CD73/adenosine pathway (AACR 2024) - "In vivo efficacy of CBO421 monotherapy was evaluated in a syngeneic mouse model.Results CBO421 exhibited a binding affinity to human CD73 (KD = 0.8 nM) that was comparable to or greater to the affinity observed with small molecule inhibitors (AB680, OP-5244) and CD73-targeting mAbs (oleclumab, mupadolimab biosimilars). CBO421 demonstrated high potency in functional cell-based assays and robust antitumor efficacy in a syngeneic mouse model. Currently, CBO421 is being advanced as a clinical development candidate for the treatment of solid cancers."

Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor • CD4 • CD73 • CD8 • NT5E

CBO421, a novel drug Fc-conjugate, inhibits the enzymatic activity of CD73 and triggers CD73 internalization (AACR 2024) - "CD73 inhibition by CBO421 of soluble CD73 or CD73 expressed on the surface of the MDA-MB-231 cell line was comparable or superior to AB680 or oleclumab. Receptor internalization activities of CBO421 and oleclumab were compared. CBO421 and oleclumab internalization percentages were determined at 1 h (52.3% vs 26.7%), 4 h (80.8% vs 38.0%), and 6 h (84.8% vs 42.9%) respectively, with CBO421 demonstrating superior maximal receptor internalization."

Late-breaking abstract • Breast Cancer • Oncology • Solid Tumor • Triple Negative Breast Cancer • CD73 • CD8 • NT5E

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "In human triple-negative breast cancer cell lines, CBO421 demonstrated potent and complete CD73 enzyme inhibition and robust CD73 receptor internalization in CD73 cancer cells, superior to oleclumab, an anti-CD73 monoclonal antibody."

Preclinical • Oncology • Solid Tumor • Triple Negative Breast Cancer

Cidara Therapeutics Presents Promising New Data on Novel Drug-Fc Conjugate Candidates at the American Association for Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "CBO421 demonstrated strong binding affinity and potent inhibition of both soluble and membrane bound CD73, differentiating it from monoclonal antibody CD73 inhibitors. The candidate also exhibited high potency in functional cell-based assays and robust antitumor efficacy in a syngeneic mouse model."

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics to Present Preclincal Data on Multiple Novel Drug-Fc Conjugate Candidates at American Association dor Cancer Research (AACR) Annual Meeting 2024 (GlobeNewswire) - "Cidara Therapeutics, Inc...today announced the company will be presenting three abstracts and one late-breaking abstract during the American Association for Cancer Research (AACR) Annual Meeting to be held April 5-10, 2024 at the San Diego Convention Center in San Diego, California."

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics Presents New Promising Preclincal Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire) - "Cidara Therapeutics, Inc...announced the presentation of new preclinical data on its novel, multi-specific CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara also presented new preclinical data on CBO421...'Dual inhibition of both CD73 and PD-1 checkpoint pathways with a single DFC contributed to significant tumor growth reduction, highlighting the potential clinical benefits of this first-in-class multi-specific inhibitor derived from our Cloudbreak platform.'...Cidara is currently advancing its dual CD73/PD-1 inhibitor DFC and CBO421 in preclinical studies. The company plans to file an investigational new drug (IND) application in mid-2024 for CBO421."

IND • Preclinical • Solid Tumor

Cidara Therapeutics to Present New Preclinical Data on Novel Dual-Acting Drug-Fc Conjugates at ESMO Immuno-Oncology Annual Congress (GlobeNewswire) - "Cidara Therapeutics...announced the company will present new preclinical data on its novel, dual-acting CD73/PD-1 targeting drug-Fc conjugate (DFC) candidate at the ESMO Immuno-Oncology (IO) Annual Congress. Cidara will also present new preclinical data on CBO421, its first-in-class CD73 targeting DFC. The conference is taking place December 6-8, 2023, virtually and in-person in Geneva, Switzerland."

Preclinical • Solid Tumor

Discovery of CBO421, a first-in-class Drug Fc-Conjugate (DFC), targeting CD73 in Cancer (ESMO-IO 2023) - "Conclusions CBO421 demonstrated high potency, combined with multiple, distinct mechanisms of action that translated to potent antitumor activity as a monotherapy in syngeneic mouse models that was further improved in combination with PD-1 therapy. Based on these results and other emerging data, CBO421 is being advanced as a clinical development candidate for the treatment of solid cancers."

Oncology • Solid Tumor • CD8 • GZMB • IL2RA • NT5E

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting (GlobeNewswire) - "Cidara Therapeutics...announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting....'CBO421, our CD73-targeting DFC, combines the strengths of small molecule inhibitors and monoclonal antibodies against CD73 and demonstrates the potential for best-in-class activity to fully exploit the CD73 target to inhibit immune evasion by cancer cells in-vivo. Based on these data, we’re excited to advance this candidate into clinical trials for the treatment of solid tumors'."

Preclinical • Solid Tumor

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting (GlobeNewswire) - "Cidara Therapeutics, Inc...today announced new preclinical data on its drug-Fc conjugate (DFC) candidate, CBO421, at the Society for Immunotherapy of Cancer (SITC)’s 38th Annual Meeting. The conference is taking place November 1-5, 2023, both virtually and in-person in San Diego, CA....'CBO421, our CD73-targeting DFC, combines the strengths of small molecule inhibitors and monoclonal antibodies against CD73 and demonstrates the potential for best-in-class activity to fully exploit the CD73 target to inhibit immune evasion by cancer cells in-vivo.'"

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics Presents Preclinical Data on Novel Drug-Fc Conjugate CBO421 at SITC’s 38ᵗʰ Annual Meeting (GlobeNewswire) - "'We look forward to sharing data that demonstrate the potential for CBO421 to potently inhibit tumor growth as both a monotherapy and in combination with PD-1 therapies,'...CBO421, our CD73-targeting DFC, combines the strengths of small molecule inhibitors and monoclonal antibodies against CD73 and demonstrates the potential for best-in-class activity to fully exploit the CD73 target to inhibit immune evasion by cancer cells in-vivo."

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics to Present Ongoing Development of Drug-Fc Conjugates (DFC) Including CD73-Targeting DFC From Its Cloudbreak Platform at Adenosine-Pathway Targeted Cancer Immunotherapy Summit (GlobeNewswire) - "Cidara Therapeutics...announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting drug-Fc conjugate (DFC), as well as the development of its novel DFCs from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023....'We believe CD421 combines the best attributes of small molecule and monoclonal antibody therapies and can serve as a potentially beneficial alternative treatment option for patients with cancer'."

Preclinical • Oncology

Cidara Therapeutics to Present at Adenosine Pathway Targeted Cancer Immunotherapy Summit (GlobeNewswire) - "Cidara Therapeutics, Inc...today announced that the company will deliver an oral presentation including highlights from its ongoing preclinical studies of CD421, a CD73-targeting DFC candidate, as well as the development of its novel drug-Fc conjugates (DFCs) from Cidara’s Cloudbreak® platform, at the 2nd Annual Adenosine-Pathway Targeted Cancer Immunotherapy Summit in Boston, MA, which is being held June 20-22, 2023."

Preclinical • Oncology • Solid Tumor

Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2023 Financial Results (GlobeNewswire) - "...'We expect to file an Investigational New Drug Application (IND) in 2024 for our first oncology DFC candidate, CD421, a potential first-in-class inhibitor of CD73'."

IND • Oncology • Solid Tumor

Discovery of CBO-212, a first-in-class drug Fc-conjugate (DFC), targeting CD73 in cancer (ESMO-TAT 2023) - "The in vitro potency and favorable PK of CBO-212 translated to significant TGI in a syngeneic model with a single dose. Based on these results CBO-212 is being advanced as a clinical development candidate for the treatment of solid cancers."

Colon Cancer • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

Cidara Therapeutics Presents Preclinical Data on CD73-Targeting Drug-Fc Conjugate at the 2023 ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) - "Cidara Therapeutics...presented preclinical data on a CD73-targeting drug-Fc conjugate (DFC) candidate, CBO-212, from the Company’s Cloudbreak® platform, at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023....CBO-212 restored activation of human peripheral blood mononuclear cells suppressed with adenosine monophosphate to a greater extent than the mAb comparators, and similar to the small molecule inhibitors tested. Unlike tested small molecule inhibitors currently in development, the multivalent presentation of CD73 inhibitors on CBO-212 induced receptor internalization and subsequent reduction of CD73 receptors expressed on a human breast cancer cell line."

Preclinical • Breast Cancer • Oncology • Solid Tumor

Cidara to Present at ESMO Targeted Anticancer Therapies Congress (GlobeNewswire) - "Cidara Therapeutics, Inc...today announced that it will present highlights from pharmacokinetic studies of a CD73-targeting drug-Fc conjugate (DFC) oncology candidate from the Company’s Cloudbreak® platform at the ESMO Targeted Anticancer Therapies Congress (ESMO TAT) in Paris, March 6-8, 2023. The studies evaluated the inhibition of CD73 in cell-free and cell-based assays....CD73 is highly expressed on a variety of tumor and stromal cells as well as immunosuppressive cell populations, such as regulatory T cells and myeloid-derived suppressor cells. CD421 is designed to address the potency, efficacy, pharmacokinetic and safety limitations of small molecule and monoclonal antibody candidates targeting CD73." "

Preclinical • Oncology • Solid Tumor